Pub Date : 2016-08-31DOI: 10.1177/8755122516667127
Alicia B. Forinash, Danielle Chamness, Abigail M. Yancey, J. Koerner, K. Mathews, Collin Miller, Judy Thompson, T. Myles
Background: Asthma complicates 4% to 8% of pregnancies. The impact of clinical pharmacists providing asthma management and education to obstetric patients is unknown. Objective: Evaluate the impact of and patient satisfaction with clinical pharmacy services on asthma in pregnancy. Methods: This prospective quasi-experimental study enrolled 30 pregnant patients with asthma and assessed perceived asthma understanding, control, and inhaler technique before and after a clinical pharmacist visit and education. The primary outcome was change in pre- and postsurvey scores. Items were rated on a 5-point Likert-type scale; higher scores represented higher perceived knowledge or satisfaction. Secondary outcomes included inhaler technique scores, asthma control, correlating patient-specific factors with the primary outcome, and level of patient satisfaction with clinical pharmacy services. Results: Perceived knowledge of asthma in pregnancy median score (maximum score 50) significantly increased with clinical pharmacy education (37.5 pre vs 49 post, P = .001). Prior to clinical pharmacy services, patients highly rated their perceived knowledge of asthma in pregnancy with median scores on 7 of 10 items between 4 and 5. Despite this, significant changes were observed on 9 items. The proportion of patients with controlled asthma significantly increased after the pharmacist visit (33.3% vs 90%, P < .001). Satisfaction with clinical pharmacy services was overwhelmingly positive with average scores on all items 4.5 to 5. Inhaler technique scores significantly increased from baseline to follow-up (4 vs 7, P = .001). Conclusions: Pharmacists significantly improved patient perceived knowledge about asthma, asthma control, and inhaler technique. Patients were overwhelmingly satisfied with the care provided by the pharmacist.
背景:妊娠期哮喘并发症发生率为4%至8%。临床药师为产科患者提供哮喘管理和教育的影响尚不清楚。目的:评价临床药学服务对妊娠期哮喘的影响及患者满意度。方法:本前瞻性准实验研究纳入了30例妊娠哮喘患者，并在临床药师拜访和教育前后评估其对哮喘的认知、控制和吸入器技术。主要结果是调查前和调查后得分的变化。项目按照李克特5分量表进行评分;得分越高，表示认知知识或满意度越高。次要结局包括吸入器技术评分、哮喘控制、患者特异性因素与主要结局的相关性以及患者对临床药学服务的满意度。结果:临床药学教育显著提高妊娠期哮喘认知知识中位数(最高50分)(前37.5分vs后49分，P = .001)。在接受临床药学服务之前，患者对自己对妊娠期哮喘认知程度的评价较高，10个项目中有7个项目的中位数得分在4到5之间。尽管如此，在9个项目上观察到显著的变化。药师访视后哮喘得到控制的患者比例显著增加(33.3% vs 90%， P < 0.001)。对临床药学服务的满意度绝大多数是积极的，所有项目的平均得分为4.5至5分。吸入器技术评分从基线到随访显著增加(4比7,P = .001)。结论:药师显著提高了患者对哮喘、哮喘控制和吸入器技术的认知。病人对药剂师提供的治疗非常满意。
{"title":"Impact of Clinical Pharmacy on Asthma in Pregnancy in a Maternal-Fetal Care Clinic","authors":"Alicia B. Forinash, Danielle Chamness, Abigail M. Yancey, J. Koerner, K. Mathews, Collin Miller, Judy Thompson, T. Myles","doi":"10.1177/8755122516667127","DOIUrl":"https://doi.org/10.1177/8755122516667127","url":null,"abstract":"Background: Asthma complicates 4% to 8% of pregnancies. The impact of clinical pharmacists providing asthma management and education to obstetric patients is unknown. Objective: Evaluate the impact of and patient satisfaction with clinical pharmacy services on asthma in pregnancy. Methods: This prospective quasi-experimental study enrolled 30 pregnant patients with asthma and assessed perceived asthma understanding, control, and inhaler technique before and after a clinical pharmacist visit and education. The primary outcome was change in pre- and postsurvey scores. Items were rated on a 5-point Likert-type scale; higher scores represented higher perceived knowledge or satisfaction. Secondary outcomes included inhaler technique scores, asthma control, correlating patient-specific factors with the primary outcome, and level of patient satisfaction with clinical pharmacy services. Results: Perceived knowledge of asthma in pregnancy median score (maximum score 50) significantly increased with clinical pharmacy education (37.5 pre vs 49 post, P = .001). Prior to clinical pharmacy services, patients highly rated their perceived knowledge of asthma in pregnancy with median scores on 7 of 10 items between 4 and 5. Despite this, significant changes were observed on 9 items. The proportion of patients with controlled asthma significantly increased after the pharmacist visit (33.3% vs 90%, P < .001). Satisfaction with clinical pharmacy services was overwhelmingly positive with average scores on all items 4.5 to 5. Inhaler technique scores significantly increased from baseline to follow-up (4 vs 7, P = .001). Conclusions: Pharmacists significantly improved patient perceived knowledge about asthma, asthma control, and inhaler technique. Patients were overwhelmingly satisfied with the care provided by the pharmacist.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":"32 1","pages":"240 - 244"},"PeriodicalIF":1.0,"publicationDate":"2016-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81420256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-07-28DOI: 10.1177/8755122516661736
C. White
Objective: Compare and contrast systematic reviews/meta-analyses assessing the time in the therapeutic range (TTR) for vitamin K antagonists (VKAs), clinical impact, and predictors. Data Sources: OVID MEDLINE search (1980-June 1, 2016) using the terms “vitamin K antagonist or warfarin” and “systematic review or meta-analysis” with backwards citation tracking from procured articles. Study Selection and Data Extraction: Search results were limited to systematic reviews assessing TTR with VKAs in patients with atrial fibrillation (AF) or venous thromboembolism (VTE). Data Synthesis: Six systematic reviews assessed TTR (4 in AF, 2 in VTE), and 3 of those assessed control at the time of a thrombotic or bleeding event (2 in AF, 1 in VTE). In patients on VKAs, greater TTR is correlated with fewer thromboembolic events and bleeding complications. VKA naïve patients have a harder time maintaining TTR than those with a previous knowledge of the likely therapeutic dose. Patients in the United States spend less TTR than those in other countries. Randomized clinical trials and anticoagulation clinics achieve greater TTR than those treated outside of these settings. The overall TTR has not improved from the first systematic reviews to the newest ones even though they were conducted 10 years apart and contained many new studies. Also, TTR in AF and VTE is similar. Conclusions: TTR is an important metric of VKA efficacy and safety and needs to be optimized. Many factors such as being VKA naïve can compromise TTR, and the use of anticoagulation clinics to optimize therapy is an important approach.
{"title":"INR Stability, Clinical Importance, and Predictors in Patients With Atrial Fibrillation and Venous Thromboembolism Receiving Vitamin K Antagonists","authors":"C. White","doi":"10.1177/8755122516661736","DOIUrl":"https://doi.org/10.1177/8755122516661736","url":null,"abstract":"Objective: Compare and contrast systematic reviews/meta-analyses assessing the time in the therapeutic range (TTR) for vitamin K antagonists (VKAs), clinical impact, and predictors. Data Sources: OVID MEDLINE search (1980-June 1, 2016) using the terms “vitamin K antagonist or warfarin” and “systematic review or meta-analysis” with backwards citation tracking from procured articles. Study Selection and Data Extraction: Search results were limited to systematic reviews assessing TTR with VKAs in patients with atrial fibrillation (AF) or venous thromboembolism (VTE). Data Synthesis: Six systematic reviews assessed TTR (4 in AF, 2 in VTE), and 3 of those assessed control at the time of a thrombotic or bleeding event (2 in AF, 1 in VTE). In patients on VKAs, greater TTR is correlated with fewer thromboembolic events and bleeding complications. VKA naïve patients have a harder time maintaining TTR than those with a previous knowledge of the likely therapeutic dose. Patients in the United States spend less TTR than those in other countries. Randomized clinical trials and anticoagulation clinics achieve greater TTR than those treated outside of these settings. The overall TTR has not improved from the first systematic reviews to the newest ones even though they were conducted 10 years apart and contained many new studies. Also, TTR in AF and VTE is similar. Conclusions: TTR is an important metric of VKA efficacy and safety and needs to be optimized. Many factors such as being VKA naïve can compromise TTR, and the use of anticoagulation clinics to optimize therapy is an important approach.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":"92 1","pages":"253 - 259"},"PeriodicalIF":1.0,"publicationDate":"2016-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79999478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-07-12DOI: 10.1177/8755122516658767
Alicia B. Forinash, Danielle Chamness, Abigail M. Yancey, K. Mathews, Collin Miller, Judy Thompson, T. Myles
Objective: To evaluate physician satisfaction with clinical pharmacy services in an obstetrics teaching clinic. Study Design: A 35-question survey was created to evaluate demographics and provider satisfaction with clinical pharmacy services using 5-point Likert scale and open response questions. Surveys were administered to all clinic attendings, maternal fetal medicine fellows, and OB/Gyn residents in June 2014 via Survey Monkey. Results: Thirty-one physicians (83.8%) completed the survey. The first set of questions utilized a 5-point Likert-type scale ranging from “poor” (1) to “excellent” (5) and evaluated respondents’ impressions of the clinical pharmacists’ clinical knowledge and professional behavior. The median score was 5 (“excellent”) on all items in the survey, and many demonstrated an average response of 4.81 to 4.9 or higher, demonstrating that almost all respondents chose “excellent.” The next set of questions assessed the clinical pharmacist’s role with the clinic’s multidisciplinary team and asked respondents to answer questions based on a 5-point Likert-type scale ranging from “strongly disagree” (1) to “strongly agree” (5). The majority of responses to questions in this section were between 4.19 and 4.84. Reasons for referring patients to the clinical pharmacist were smoking cessation, asthma management, psych medication use/issues, adherence/polypharmacy, medication reconciliation, counseling on medication safety in pregnancy, insulin/heparin administration, and substance abuse. Conclusions: Overall, the survey identified a positive response and high level of physician satisfaction with clinical pharmacy services. Clinical pharmacy has the capacity to enhance pregnancy care and should be more routinely integrated into the prenatal care team.
{"title":"Physician Satisfaction With Clinical Pharmacist Services in an Obstetrics and Gynecology Teaching Clinic","authors":"Alicia B. Forinash, Danielle Chamness, Abigail M. Yancey, K. Mathews, Collin Miller, Judy Thompson, T. Myles","doi":"10.1177/8755122516658767","DOIUrl":"https://doi.org/10.1177/8755122516658767","url":null,"abstract":"Objective: To evaluate physician satisfaction with clinical pharmacy services in an obstetrics teaching clinic. Study Design: A 35-question survey was created to evaluate demographics and provider satisfaction with clinical pharmacy services using 5-point Likert scale and open response questions. Surveys were administered to all clinic attendings, maternal fetal medicine fellows, and OB/Gyn residents in June 2014 via Survey Monkey. Results: Thirty-one physicians (83.8%) completed the survey. The first set of questions utilized a 5-point Likert-type scale ranging from “poor” (1) to “excellent” (5) and evaluated respondents’ impressions of the clinical pharmacists’ clinical knowledge and professional behavior. The median score was 5 (“excellent”) on all items in the survey, and many demonstrated an average response of 4.81 to 4.9 or higher, demonstrating that almost all respondents chose “excellent.” The next set of questions assessed the clinical pharmacist’s role with the clinic’s multidisciplinary team and asked respondents to answer questions based on a 5-point Likert-type scale ranging from “strongly disagree” (1) to “strongly agree” (5). The majority of responses to questions in this section were between 4.19 and 4.84. Reasons for referring patients to the clinical pharmacist were smoking cessation, asthma management, psych medication use/issues, adherence/polypharmacy, medication reconciliation, counseling on medication safety in pregnancy, insulin/heparin administration, and substance abuse. Conclusions: Overall, the survey identified a positive response and high level of physician satisfaction with clinical pharmacy services. Clinical pharmacy has the capacity to enhance pregnancy care and should be more routinely integrated into the prenatal care team.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":"19 1","pages":"191 - 195"},"PeriodicalIF":1.0,"publicationDate":"2016-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75017113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-07-04DOI: 10.1177/8755122516657566
Bethany W. Ibach, Peter N. Johnson, K. Ernst, D. Harrison, Jamie L. Miller
Background: Methadone and morphine are commonly used to treat neonatal abstinence syndrome (NAS). Limited data exist to describe the most appropriate initial doses and taper regimens of these agents. Objectives: Describe the median initial dose and frequency of methadone and morphine for NAS. Compare dose adjustments, time to symptom relief, and taper complexity between groups. Methods: Retrospective study of neonates receiving enteral methadone or morphine for NAS over a 4-year period. Data collection included medication regimen, abstinence scores based on the Modified Finnegan Neonatal Abstinence Scoring Tool, and adverse events. Planned home taper complexity was assessed using the Medication Taper Complexity Score–Revised (MTCS-R). The primary outcome was initial opioid dose. Secondary outcomes included number of dose adjustments, time to symptom relief, and MTCS-R score. Results: Fifty neonates were initially treated for NAS with methadone (n = 36) or morphine (n = 14). The median initial dose was 0.09 mg/kg (range = 0.03-0.2) for methadone and 0.04 mg/kg (range = 0.03-0.4) for morphine. The most common initial dosing interval was q8h for methadone versus q3h for morphine. Number of dose adjustments and time to symptom relief were similar between groups. Median MTCS-R scores were similar between groups. There was no difference in adverse events between groups. Limitations included small sample size, preference toward methadone use, and variability of initial opioid dosing and titration. Conclusions: There was significant variability in initial doses of both agents. Neonates receiving methadone required less frequent dosing than morphine, which may result in easier administration and may allow for safer outpatient administration.
{"title":"Initial Dosing and Taper Complexity of Methadone and Morphine for Treatment of Neonatal Abstinence Syndrome","authors":"Bethany W. Ibach, Peter N. Johnson, K. Ernst, D. Harrison, Jamie L. Miller","doi":"10.1177/8755122516657566","DOIUrl":"https://doi.org/10.1177/8755122516657566","url":null,"abstract":"Background: Methadone and morphine are commonly used to treat neonatal abstinence syndrome (NAS). Limited data exist to describe the most appropriate initial doses and taper regimens of these agents. Objectives: Describe the median initial dose and frequency of methadone and morphine for NAS. Compare dose adjustments, time to symptom relief, and taper complexity between groups. Methods: Retrospective study of neonates receiving enteral methadone or morphine for NAS over a 4-year period. Data collection included medication regimen, abstinence scores based on the Modified Finnegan Neonatal Abstinence Scoring Tool, and adverse events. Planned home taper complexity was assessed using the Medication Taper Complexity Score–Revised (MTCS-R). The primary outcome was initial opioid dose. Secondary outcomes included number of dose adjustments, time to symptom relief, and MTCS-R score. Results: Fifty neonates were initially treated for NAS with methadone (n = 36) or morphine (n = 14). The median initial dose was 0.09 mg/kg (range = 0.03-0.2) for methadone and 0.04 mg/kg (range = 0.03-0.4) for morphine. The most common initial dosing interval was q8h for methadone versus q3h for morphine. Number of dose adjustments and time to symptom relief were similar between groups. Median MTCS-R scores were similar between groups. There was no difference in adverse events between groups. Limitations included small sample size, preference toward methadone use, and variability of initial opioid dosing and titration. Conclusions: There was significant variability in initial doses of both agents. Neonates receiving methadone required less frequent dosing than morphine, which may result in easier administration and may allow for safer outpatient administration.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":"11 1","pages":"216 - 222"},"PeriodicalIF":1.0,"publicationDate":"2016-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90768884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-06-23DOI: 10.1177/8755122516655544
Kayla M. Natali, J. Goldman
Objective: A case of insulin allergy to insulin aspart, insulin aspart protamine/insulin aspart 70/30, insulin lispro, and insulin lispro protamine/insulin lispro 75/25 in a patient with type 2 diabetes mellitus is reported. Case Summary: A 76-year-old Caucasian male weighing 81 kg presented with complaints of burning, lumps, and a rash where his insulin aspart protamine/insulin aspart 70/30 was injected 2 months after initiation. Because poor injection technique can mimic insulin allergy, the patient was counseled again on proper injection technique. The patient presented 2 weeks later with the same complaints. Insulin aspart protamine/insulin aspart 70/30 was discontinued and insulin lispro protamine/insulin lispro 75/25 was initiated. The patient presented 3 months later with a localized reaction. Insulin lispro protamine/insulin lispro 75/25 was discontinued and insulin U100 glargine and insulin lispro were initiated. One week later, the patient still had complaints of a localized reaction and was referred to an allergist for testing. Skin prick tests revealed insulin allergy to insulin aspart and insulin lispro but not to insulin U100 glargine or insulin glulisine. The patient’s regimen was changed to insulin U100 glargine and insulin glulisine, and he has not experienced any reaction since. Discussion: Allergic reactions to human insulin preparations are rare and may present as a localized reaction or a generalized reaction. Different types of allergic reactions to human insulin have been reported, including type I, type III, and type IV hypersensitivity reactions. If insulin allergy is suspected, the following steps should be taken to confirm such allergy: evaluation of injection technique, switching to a different insulin preparation, and referral to an allergist for allergy testing if necessary. Conclusion: A patient with type 2 diabetes mellitus experienced a type I hypersensitivity reaction to insulin aspart, insulin aspart protamine/insulin aspart 70/30, insulin lispro, and insulin lispro protamine/insulin lispro 75/25.
{"title":"Insulin Allergy","authors":"Kayla M. Natali, J. Goldman","doi":"10.1177/8755122516655544","DOIUrl":"https://doi.org/10.1177/8755122516655544","url":null,"abstract":"Objective: A case of insulin allergy to insulin aspart, insulin aspart protamine/insulin aspart 70/30, insulin lispro, and insulin lispro protamine/insulin lispro 75/25 in a patient with type 2 diabetes mellitus is reported. Case Summary: A 76-year-old Caucasian male weighing 81 kg presented with complaints of burning, lumps, and a rash where his insulin aspart protamine/insulin aspart 70/30 was injected 2 months after initiation. Because poor injection technique can mimic insulin allergy, the patient was counseled again on proper injection technique. The patient presented 2 weeks later with the same complaints. Insulin aspart protamine/insulin aspart 70/30 was discontinued and insulin lispro protamine/insulin lispro 75/25 was initiated. The patient presented 3 months later with a localized reaction. Insulin lispro protamine/insulin lispro 75/25 was discontinued and insulin U100 glargine and insulin lispro were initiated. One week later, the patient still had complaints of a localized reaction and was referred to an allergist for testing. Skin prick tests revealed insulin allergy to insulin aspart and insulin lispro but not to insulin U100 glargine or insulin glulisine. The patient’s regimen was changed to insulin U100 glargine and insulin glulisine, and he has not experienced any reaction since. Discussion: Allergic reactions to human insulin preparations are rare and may present as a localized reaction or a generalized reaction. Different types of allergic reactions to human insulin have been reported, including type I, type III, and type IV hypersensitivity reactions. If insulin allergy is suspected, the following steps should be taken to confirm such allergy: evaluation of injection technique, switching to a different insulin preparation, and referral to an allergist for allergy testing if necessary. Conclusion: A patient with type 2 diabetes mellitus experienced a type I hypersensitivity reaction to insulin aspart, insulin aspart protamine/insulin aspart 70/30, insulin lispro, and insulin lispro protamine/insulin lispro 75/25.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":"12 1","pages":"210 - 215"},"PeriodicalIF":1.0,"publicationDate":"2016-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86698297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-06-23DOI: 10.1177/8755122516653970
Zachary Mueller, Kaitlyn Craddock, Jamie M. Pitlick, Andrew J. Crannage
Objective: To evaluate the safety and efficacy of 2 human monoclonal antibodies, alirocumab and evolocumab, on reduction of low-density lipoprotein cholesterol (LDL-C), cardiovascular benefits, and their place in current practice. Data Sources: A search of MEDLINE and Scopus databases (1966 to May 2016) with search terms “alirocumab,” “evolocumab,” “LDL,” and “PCSK9.” Study Selection and Data Extraction: The search identified phase 3 randomized control trials in English language in the past 10 years that studied LDL-C reduction of alirocumab or evolocumab. The studies were assessed for all efficacy and safety endpoints. Data Synthesis: Twelve total studies were identified evaluating alirocumab or evolocumab. These monoclonal antibodies have been shown to significantly decrease LDL-C as monotherapy and in combination with statins in phase 3 clinical trials in patients with primary hypercholesterolemia as well as familial hypercholesterolemia by inhibiting PCSK9. Alirocumab significantly reduced LDL-C by up to 61%, while evolocumab significantly reduced LDL-C by up to 66%. Adverse effects of these medications have been low and overall well tolerated. Conclusion: Although these monoclonal antibodies have shown to significantly reduce LDL-C, their effect on cardiovascular outcomes has not yet been determined. Further studies are being conducted to assess the cardiovascular benefit of both alirocumab and evolocumab. Until these studies demonstrate a reduction in atherosclerotic cardiovascular disease risk, statins should remain first-line therapy for most patients. However, alirocumab and evolocumab can be used as an effective adjunctive therapy option to lower LDL-C or in patients who are statin intolerant.
{"title":"PCSK9 Inhibitors","authors":"Zachary Mueller, Kaitlyn Craddock, Jamie M. Pitlick, Andrew J. Crannage","doi":"10.1177/8755122516653970","DOIUrl":"https://doi.org/10.1177/8755122516653970","url":null,"abstract":"Objective: To evaluate the safety and efficacy of 2 human monoclonal antibodies, alirocumab and evolocumab, on reduction of low-density lipoprotein cholesterol (LDL-C), cardiovascular benefits, and their place in current practice. Data Sources: A search of MEDLINE and Scopus databases (1966 to May 2016) with search terms “alirocumab,” “evolocumab,” “LDL,” and “PCSK9.” Study Selection and Data Extraction: The search identified phase 3 randomized control trials in English language in the past 10 years that studied LDL-C reduction of alirocumab or evolocumab. The studies were assessed for all efficacy and safety endpoints. Data Synthesis: Twelve total studies were identified evaluating alirocumab or evolocumab. These monoclonal antibodies have been shown to significantly decrease LDL-C as monotherapy and in combination with statins in phase 3 clinical trials in patients with primary hypercholesterolemia as well as familial hypercholesterolemia by inhibiting PCSK9. Alirocumab significantly reduced LDL-C by up to 61%, while evolocumab significantly reduced LDL-C by up to 66%. Adverse effects of these medications have been low and overall well tolerated. Conclusion: Although these monoclonal antibodies have shown to significantly reduce LDL-C, their effect on cardiovascular outcomes has not yet been determined. Further studies are being conducted to assess the cardiovascular benefit of both alirocumab and evolocumab. Until these studies demonstrate a reduction in atherosclerotic cardiovascular disease risk, statins should remain first-line therapy for most patients. However, alirocumab and evolocumab can be used as an effective adjunctive therapy option to lower LDL-C or in patients who are statin intolerant.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":"12 1","pages":"201 - 209"},"PeriodicalIF":1.0,"publicationDate":"2016-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75323423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-06-08DOI: 10.1177/8755122516653611
N. Borja‐Hart, Bethany G. Leachman
Background: Community pharmacists are a highly utilized drug information resource for patients and health care providers. Good retrieval skills and the availability of credible references are key to providing necessary information. Objective: This study aimed to identify the types of drug information resources used by chain community pharmacists in Tennessee. Methods: A phone survey was conducted by a trained pharmacy student to 39 pharmacists working at chain community pharmacies. Demographic questions, types of drug information resources available, Internet availability, smartphone applications (apps) used, and most common drug information questions received were identified. Results: Electronic tertiary drug resources were used by the majority of pharmacists, with the top 2 resources being Clinical Pharmacology and Facts and Comparisons. Seventy-four percent of pharmacists surveyed used smartphone apps to access information more quickly. Few pharmacists stated access to primary literature, while 4 pharmacists cited using the secondary resource PubMed. The 2 most commonly asked questions were concerning adverse drug reactions and side effects. Conclusions: Electronic drug information resources are widely available and utilized. In order to comply with all of the demands that a pharmacists comes across, these resources need to be very familiar and easy to operate from an efficiency stand-point.
{"title":"Drug Information Resources Used by Chain Community Pharmacists in Tennessee","authors":"N. Borja‐Hart, Bethany G. Leachman","doi":"10.1177/8755122516653611","DOIUrl":"https://doi.org/10.1177/8755122516653611","url":null,"abstract":"Background: Community pharmacists are a highly utilized drug information resource for patients and health care providers. Good retrieval skills and the availability of credible references are key to providing necessary information. Objective: This study aimed to identify the types of drug information resources used by chain community pharmacists in Tennessee. Methods: A phone survey was conducted by a trained pharmacy student to 39 pharmacists working at chain community pharmacies. Demographic questions, types of drug information resources available, Internet availability, smartphone applications (apps) used, and most common drug information questions received were identified. Results: Electronic tertiary drug resources were used by the majority of pharmacists, with the top 2 resources being Clinical Pharmacology and Facts and Comparisons. Seventy-four percent of pharmacists surveyed used smartphone apps to access information more quickly. Few pharmacists stated access to primary literature, while 4 pharmacists cited using the secondary resource PubMed. The 2 most commonly asked questions were concerning adverse drug reactions and side effects. Conclusions: Electronic drug information resources are widely available and utilized. In order to comply with all of the demands that a pharmacists comes across, these resources need to be very familiar and easy to operate from an efficiency stand-point.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":"22 1","pages":"185 - 190"},"PeriodicalIF":1.0,"publicationDate":"2016-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84678812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-05-13DOI: 10.1177/8755122516646384
J. J. Peterson, J. Hoehns
Objective: To review literature regarding direct oral anticoagulants (DOACs) and determine their viability of administration in solution or via enteral tubes. Data Sources: MEDLINE literature searches identified articles published 2007-present using MeSH terms: factor Xa inhibitors, antithrombins, biological availability, and enteral nutrition. Package inserts were included. Manufacturers were asked to provide literature. Study Selection and Data Extraction: We included studies emphasizing bioavailability or enteral administration. Data Synthesis: Dabigatran and edoxaban package inserts recommend against altering the dosage form, and against enteral administration. One rivaroxaban study was identified. Given with food, enteral administration was comparable to the oral tablet. The mean AUC (0.889, 90% CI 86.12-91.84%) was within the equivalency margins; however Cmax (0.820, 90% CI 78.84-85.86%) was slightly below the 80% threshold. One apixaban study was identified. They showed bioequivalence between oral and enteral administration in different vehicles, but decreased bioavailability when crushed tablets were given along with nutritional support. AUC and Cmax were 32% and 19% lower, respectively, when apixaban solution was given via nasogastric (NG) tube with nutritional supplement versus oral administration of solution. Conclusions: Dabigatran capsules should not be altered, due to large variations in drug exposure. Rivaroxaban can be given as oral solution or via NG tube. Larger doses must be given with nutritional supplementation and enteral tubes must not be distal to the stomach. Apixaban can be given as oral solution or via nasogastric or gastric tube on an empty stomach. Food impairs bioavailability of the crushed tablets. There are insufficient data to recommend enteral administration of edoxaban and the package insert recommends against altering tablets.
目的:回顾有关直接口服抗凝剂(DOACs)的文献，并确定其在溶液或肠内管给药方面的可行性。数据来源:MEDLINE文献检索确定2007年至今发表的文章，使用MeSH术语:Xa因子抑制剂、抗凝血酶、生物利用度和肠内营养。包括包装说明书。制造商被要求提供文献资料。研究选择和数据提取:我们纳入了强调生物利用度或肠内给药的研究。资料综合:达比加群和依多沙班的说明书不建议改变剂型，也不建议肠内给药。一项利伐沙班研究被确认。与食物一起给药，肠内给药与口服片剂相当。平均AUC (0.889, 90% CI 86.12-91.84%)在等效范围内;Cmax (0.820, 90% CI 78.84 ~ 85.86%)略低于80%的阈值。一项阿哌沙班研究被确认。在不同的载体中口服和肠内给药表现出生物等效性，但当粉碎片剂与营养支持一起给药时，生物利用度降低。与口服阿哌沙班溶液相比，经鼻胃管加营养补充给予阿哌沙班溶液的AUC和Cmax分别降低32%和19%。结论:达比加群胶囊不应该改变，因为药物暴露有很大的变化。利伐沙班可口服或经胃管给药。必须在营养补充的同时给予更大剂量，肠内管不能离胃很远。阿哌沙班可作为口服溶液或通过鼻胃管或胃管在空腹给予。食物会损害压碎片剂的生物利用度。没有足够的数据来推荐肠内使用依多沙班，包装说明书也不建议更换片剂。
{"title":"Administration of Direct Oral Anticoagulants Through Enteral Feeding Tubes","authors":"J. J. Peterson, J. Hoehns","doi":"10.1177/8755122516646384","DOIUrl":"https://doi.org/10.1177/8755122516646384","url":null,"abstract":"Objective: To review literature regarding direct oral anticoagulants (DOACs) and determine their viability of administration in solution or via enteral tubes. Data Sources: MEDLINE literature searches identified articles published 2007-present using MeSH terms: factor Xa inhibitors, antithrombins, biological availability, and enteral nutrition. Package inserts were included. Manufacturers were asked to provide literature. Study Selection and Data Extraction: We included studies emphasizing bioavailability or enteral administration. Data Synthesis: Dabigatran and edoxaban package inserts recommend against altering the dosage form, and against enteral administration. One rivaroxaban study was identified. Given with food, enteral administration was comparable to the oral tablet. The mean AUC (0.889, 90% CI 86.12-91.84%) was within the equivalency margins; however Cmax (0.820, 90% CI 78.84-85.86%) was slightly below the 80% threshold. One apixaban study was identified. They showed bioequivalence between oral and enteral administration in different vehicles, but decreased bioavailability when crushed tablets were given along with nutritional support. AUC and Cmax were 32% and 19% lower, respectively, when apixaban solution was given via nasogastric (NG) tube with nutritional supplement versus oral administration of solution. Conclusions: Dabigatran capsules should not be altered, due to large variations in drug exposure. Rivaroxaban can be given as oral solution or via NG tube. Larger doses must be given with nutritional supplementation and enteral tubes must not be distal to the stomach. Apixaban can be given as oral solution or via nasogastric or gastric tube on an empty stomach. Food impairs bioavailability of the crushed tablets. There are insufficient data to recommend enteral administration of edoxaban and the package insert recommends against altering tablets.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":"55 1","pages":"196 - 200"},"PeriodicalIF":1.0,"publicationDate":"2016-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85838713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-05-13DOI: 10.1177/8755122516649204
R. P. Hickson, Candace J. Brancato, D. Moga
Background: Beta-blockers remain important for secondary prevention after myocardial infarction (MI). Despite clinical guideline recommendations, underutilization of this pharmacotherapy continues in patients with type 2 diabetes (T2DM) compared to the general post-MI population. Objective: This study aimed to (1) quantify the proportion of T2DM patients utilizing β-blocker therapy within 30 days of hospital discharge after MI and (2) identify clinical and demographic characteristics predicting initiation of β-blocker therapy. Methods: A retrospective cohort of US employed, commercially insured individuals was assembled using de-identified enrollment files, medical claims, and pharmacy claims from 2007 to 2009. Inclusion criteria were the following: (1) type 2 diabetes, (2) ≥18 years old, (3) continuous eligibility, (4) MI. Multivariable logistic regression with adjusted odds ratios (ORadj) using manual backward elimination was used to identify predictors of β-blocker initiation within 30 days of discharge from index hospitalization. Results: Of 341 T2DM patients, 167 (49.0%) were new users and 174 (51.0%) were nonusers of β-blockers within 30 days of post-MI hospital discharge. Patients on a calcium channel blocker (ORadj 2.63) and patients taking 1 to 5 medications (ORadj 3.59) were more likely to initiate β-blockers post-MI. Patients with heart failure (ORadj 0.45) or an arrhythmia (ORadj 0.44) were less likely to initiate β-blockers as well as patients with renal failure not taking a diuretic (ORadj 0.17). Conclusions: These results confirm previous findings that β-blockers are underutilized in T2DM patients post-MI. Predictors from the regression model can guide future research investigating how this deviation from guidelines is attributed to prescriber versus patient behavior.
{"title":"Predictors of β-Blocker Initiation After Myocardial Infarction in Patients With Type 2 Diabetes","authors":"R. P. Hickson, Candace J. Brancato, D. Moga","doi":"10.1177/8755122516649204","DOIUrl":"https://doi.org/10.1177/8755122516649204","url":null,"abstract":"Background: Beta-blockers remain important for secondary prevention after myocardial infarction (MI). Despite clinical guideline recommendations, underutilization of this pharmacotherapy continues in patients with type 2 diabetes (T2DM) compared to the general post-MI population. Objective: This study aimed to (1) quantify the proportion of T2DM patients utilizing β-blocker therapy within 30 days of hospital discharge after MI and (2) identify clinical and demographic characteristics predicting initiation of β-blocker therapy. Methods: A retrospective cohort of US employed, commercially insured individuals was assembled using de-identified enrollment files, medical claims, and pharmacy claims from 2007 to 2009. Inclusion criteria were the following: (1) type 2 diabetes, (2) ≥18 years old, (3) continuous eligibility, (4) MI. Multivariable logistic regression with adjusted odds ratios (ORadj) using manual backward elimination was used to identify predictors of β-blocker initiation within 30 days of discharge from index hospitalization. Results: Of 341 T2DM patients, 167 (49.0%) were new users and 174 (51.0%) were nonusers of β-blockers within 30 days of post-MI hospital discharge. Patients on a calcium channel blocker (ORadj 2.63) and patients taking 1 to 5 medications (ORadj 3.59) were more likely to initiate β-blockers post-MI. Patients with heart failure (ORadj 0.45) or an arrhythmia (ORadj 0.44) were less likely to initiate β-blockers as well as patients with renal failure not taking a diuretic (ORadj 0.17). Conclusions: These results confirm previous findings that β-blockers are underutilized in T2DM patients post-MI. Predictors from the regression model can guide future research investigating how this deviation from guidelines is attributed to prescriber versus patient behavior.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":"24 1","pages":"160 - 168"},"PeriodicalIF":1.0,"publicationDate":"2016-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77281595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-05-04DOI: 10.1177/8755122516644622
Poupak Rahmani, Charlotte Guzman, A. Kezouh, M. Blostein, S. Kahn
Background: Whether the level of patient’s knowledge about warfarin plays any role in maintenance of therapeutic international normalized ratio (INR) is controversial. Several studies have looked at patients’ warfarin knowledge and the level of patients’ anticoagulation control (AC). Most studies had small numbers and did not use validated questionnaires. Objectives: To use the Oral Anticoagulation Knowledge (OAK) test to assess patients’ knowledge of AC and to examine associations between knowledge, INR, and adverse events. Methods: In this cross-sectional study, patients were asked to complete the OAK test. Data on clinical and demographic characteristics, INR values, and thrombosis or bleeding events during the preceding 1 year period were collected. Associations between OAK scores, patient characteristics, proportion of therapeutic INRs, and bleeding/thrombosis events were assessed. Results: A total of 225 patients completed the OAK test. Mean (SD) age was 70 (13.4) years, 53% were male, and 75% were on warfarin for >3 years. Over the preceding year, 57.3% of INRs were therapeutic, and there were 22 bleeding and 6 thrombotic events. The mean OAK score was 12/20 (passing score = 15/20); 64% of patients failed the OAK test. Predictors of passing the OAK test were younger age (P = .01) and higher level of education (P = .03). There was no association between OAK score and proportion of therapeutic INRs, or OAK score and bleeding or thrombosis events. Conclusion: We used the OAK test to assess patients’ AC knowledge. Results suggests that while younger and more educated patients were more likely to pass the OAK test, the OAK test results may not predict INR control or occurrence of bleeding or thrombotic events.
{"title":"Association Between Patient Knowledge of Anticoagulation, INR Control, and Warfarin-Related Adverse Events","authors":"Poupak Rahmani, Charlotte Guzman, A. Kezouh, M. Blostein, S. Kahn","doi":"10.1177/8755122516644622","DOIUrl":"https://doi.org/10.1177/8755122516644622","url":null,"abstract":"Background: Whether the level of patient’s knowledge about warfarin plays any role in maintenance of therapeutic international normalized ratio (INR) is controversial. Several studies have looked at patients’ warfarin knowledge and the level of patients’ anticoagulation control (AC). Most studies had small numbers and did not use validated questionnaires. Objectives: To use the Oral Anticoagulation Knowledge (OAK) test to assess patients’ knowledge of AC and to examine associations between knowledge, INR, and adverse events. Methods: In this cross-sectional study, patients were asked to complete the OAK test. Data on clinical and demographic characteristics, INR values, and thrombosis or bleeding events during the preceding 1 year period were collected. Associations between OAK scores, patient characteristics, proportion of therapeutic INRs, and bleeding/thrombosis events were assessed. Results: A total of 225 patients completed the OAK test. Mean (SD) age was 70 (13.4) years, 53% were male, and 75% were on warfarin for >3 years. Over the preceding year, 57.3% of INRs were therapeutic, and there were 22 bleeding and 6 thrombotic events. The mean OAK score was 12/20 (passing score = 15/20); 64% of patients failed the OAK test. Predictors of passing the OAK test were younger age (P = .01) and higher level of education (P = .03). There was no association between OAK score and proportion of therapeutic INRs, or OAK score and bleeding or thrombosis events. Conclusion: We used the OAK test to assess patients’ AC knowledge. Results suggests that while younger and more educated patients were more likely to pass the OAK test, the OAK test results may not predict INR control or occurrence of bleeding or thrombotic events.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":"3 1","pages":"150 - 159"},"PeriodicalIF":1.0,"publicationDate":"2016-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72739322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：